Organization | Swiss Federal Institute of Technology

Swiss Federal Institute of Technology Report issue

Academic/Hospital Phase 1 Phase 2 Phase 4

Founded: Lausanne Switzerland (1853)

Organization Overview

First Clinical Trial

2003

NCT00174902

First Marketed Drug

None

First NDA Approval

None

Last Known Activity

2023

Timeline

NOW

Now

Alternative names

Bryn Lloyd | CIP-International Potato Center | ETH | ETH Zuerich | ETH Zurich | ETH Zürich | ETH Zurich, Switzerland | Exercise Physiology Lab, Institute of Human Movement Sciences and Sport, ETH Zurich | Human Nutrition Laboratory, ETH Zuerich | Human Nutrition Laboratory, ETH Zurich | INN | Institute for Biomedical Engineering, Swiss Federal Institute of Technology (ETH Zurich) | International Potato Center | Isabelle Herter-Aeberli | Laboratory of Human Nutrition ETH Zürich | Military Academy at ETH Zurich | Nicole Stoffel | Professor and Head, Human Nutrition, Swiss Federal Institute of Technology (ETH) Zurich, Switzerland | Prof. Michael B. Zimmermann | Swiss Federal Institute of Technology | Swiss Federal Institute of Technology (ETH) | Swiss Federal Institute of Technology (ETH,Zurich) | Swiss Federal Institute of Technology (ETH) Zurich | Swiss Federal Institute of Technology (ETH Zürich) | Swiss Federal Institute of Technology, ETH Zurich, Switzerland | Swiss Federal Institute of Technology, Institute of Behavioral Sciences | Swiss Federal Institute of Technology in Zurich (ETHZ) | Swiss Federal Institute of Technology Zurich | Women's clinc University Hospital Zurich

Active Ingredients

Drugs in Phase 4 Trials (1)

acetylcysteine (mucomyst) (1 trial)

Drugs in Phase 2 Trials (4)

acetylsalicylic acid (aspirin) (1 trial)

potassium chloride (klor-con) (1 trial)

potassium citrate (urocit-k) (1 trial)

propranolol (inderal) (1 trial)

Drugs in Phase 1 Trials (7)

benserazide (1 trial)

dextrose (1 trial)

iron (14 trials)

levodopa (larodopa) (1 trial)

vitamin a (2 trials)

vitamin d3 (1 trial)

zinc (4 trials)

Drugs in Other Trials (49)

alpha-galacto-oligosaccharides (2 trials)

amodiaquine (camoquin) (1 trial)

bovine lactoferrin (1 trial)

coffee (1 trial)

feredetate (1 trial)

ferric ammonium citrate (Ferriseltz) (1 trial)

ferric carboxymaltose (Injectafer) (2 trials)

ferric phosphate (1 trial)

ferric pyrophosphate citrate (Triferic) (5 trials)

ferric sulfate (5 trials)

ferrous bisglycinate (1 trial)

ferrous fumarate (1 trial)

ferrous sulfate (16 trials)

fish oil (Omegavan) (1 trial)

flortaucipir (Tauvid) (1 trial)

fumaric acid esters (10 trials)

galactooligosaccharide (5 trials)

human milk (1 trial)

hyaluronic acid (1 trial)

ibuprofen (motrin) (1 trial)

icosapent ethyl (vascepa) (1 trial)

inulin (1 trial)

iodine (2 trials)

iodized oil (2 trials)

iron sulfate (12 trials)

lactobacillus rhamnosus (1 trial)

lactoferrin (2 trials)

lactulose (cephulac) (1 trial)

maltodextrin (2 trials)

Meningococcal (Groups A, C, Y, W) Conjugate Vaccine (MenQuadfi) (2 trials)

millet (1 trial)

multivitamins (2 trials)

oligofructose-enriched inulin (1 trial)

omega-3 fatty acids (Omacor) (2 trials)

ovotransferrin (1 trial)

potato (1 trial)

pyrimethamine (daraprim) (1 trial)

sodium bicarbonate (1 trial)

sodium iron chlorophyllin (2 trials)

sucrose (1 trial)

sulfadoxine (1 trial)

typhoid vi polysaccharide vaccine (Typhim Vi) (1 trial)

vitamin c (7 trials)

vitamin e (1 trial)

water (2 trials)

zinc dichloride (1 trial)

zinc oxide (1 trial)

zinc sulfate (2 trials)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)

Acidosis (Phase 2)

Arteriosclerosis (Phase 2)

Behavior, Addictive (Phase 4)

Bone Diseases (Phase 2)

Cocaine-Related Disorders (Phase 4)

Night Blindness (Phase 1)

Schizotypal Personality Disorder (Phase 1)

Stress, Psychological (Phase 2)

Vitamin A Deficiency (Phase 1)

Overview

Highest Phase: Phase 4
# of Trials: 81
# of Trial APIs: 61